Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorVon Massow, Georg
dc.contributor.authorGarcia Cehic, Damir
dc.contributor.authorGregori Font, Josep
dc.contributor.authorRodríguez Frias, Francisco
dc.contributor.authorMacià, María Dolores
dc.contributor.authorEscarda, Ana
dc.contributor.authorEsteban Mur, Juan Ignacio
dc.contributor.authorQuer Sivila, Josep
dc.date.accessioned2019-07-04T05:50:36Z
dc.date.available2019-07-04T05:50:36Z
dc.date.issued2019-04-24
dc.identifier.citationvon-Massow G, Garcia-Cehic D, Gregori J, Rodriguez-Frias F, Macià MD, Escarda A, et al. Whole-genome characterization and resistance-associated substitutions in a new HCV genotype 1 subtype. Infect Drug Resist. 2019;12:947–55.
dc.identifier.issn1178-6973
dc.identifier.urihttp://hdl.handle.net/11351/4173
dc.descriptionHCV; Direct-acting antivirals; Genotype 1
dc.description.abstractHepatitis C virus (HCV) is a highly variable infectious agent, classified into 8 genotypes and 86 subtypes. Our laboratory has implemented an in-house developed high-resolution HCV subtyping method based on next-generation sequencing (NGS) for error-free classification of the virus using phylogenetic analysis and analysis of genetic distances in sequences from patient samples compared to reference sequences. During routine diagnostic, a sample from an Equatorial Guinea patient could not be classified into any of the existing subtypes. The whole genome was analyzed to confirm that the new isolate could be classified as a new HCV subtype. In addition, naturally occurring resistance-associated substitutions (RAS) were analyzed by NGS. Whole-genome analysis based on p-distances suggests that the sample belongs to a new HCV genotype 1 subtype. Several RAS in the NS3 (S122T, D168E and I170V) and NS5A protein (Q(1b)24K, R(1b)30Q and Y93L+Y93F) were found, which could limit the use of some inhibitors for treating this subtype. RAS studies of new subtypes are of great interest for tailoring treatment, as no data on treatment efficacy are reported. In our case, the patient has not yet been treated, and the RAS report will be used to design the most effective treatment.
dc.language.isoeng
dc.publisherDove Medical Press
dc.relation.ispartofseriesInfection and Drug Resistance;12
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectVirus de l'hepatitis C - Genètica
dc.subjectMedicaments antivírics
dc.subjectResistència als medicaments
dc.subject.meshHepatitis Viruses
dc.subject.mesh/genetics
dc.subject.meshDrug Resistance, Viral
dc.subject.meshGenetic Profile
dc.titleWhole-genome characterization and resistance-associated substitutions in a new HCV genotype 1 subtype
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.2147/IDR.S195441
dc.subject.decsvirus de hepatitis
dc.subject.decs/genética
dc.subject.decsfarmacorresistencia viral
dc.subject.decsperfil genético
dc.relation.publishversionhttps://www.dovepress.com/whole-genome-characterization-and-resistance-associated-substitutions--peer-reviewed-article-IDR
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[von Massow G] Grup de recerca en Malalties hepàtiques, Vall d’Hebron Institut de Recerca, Barcelona, Spain. Hospital Universitari Vall d'Hebron, Barcelona, Spain. [Garcia-Cehic D] Grup de recerca en Malalties hepàtiques, Vall d’Hebron Institut de Recerca, Barcelona, Spain. Hospital Universitari Vall d'Hebron, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. [Gregori J] Grup de recerca en Malalties hepàtiques, Vall d’Hebron Institut de Recerca, Barcelona, Spain. Hospital Universitari Vall d'Hebron, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. Roche Diagnostics S.L., Sant Cugat del Vallès, Barcelona, Spain. [Rodriguez-Frias F] Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. Sevei de Bioquimica i Microbiologia, Vall d’Hebron Institut de Recerca, Barcelona, Spain. Hospital Universitari Vall d'Hebron, Barcelona, Spain. [Macià MD] Unidad de Microbiología Molecular, Servicio de Microbiología, Instituto de Investigación Sanitaria de les Illes Balears (IdISBa), Hospital Universitario Son Espases, Mallorca, Spain. [Escarda A] Digestive Department, Hospital Universitario Son Espases, Mallorca, Spain. [Esteban JI, Quer J] Grup de recerca en Malalties hepàtiques, Vall d’Hebron Institut de Recerca, Barcelona, Spain. Hospital Universitari Vall d'Hebron, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. Departament de Medicina Universitat Autònoma de Barcelona, Barcelona, Spain.
dc.identifier.pmid31118701
dc.identifier.wosWOS:000467090600001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record